This report analyzes the merger and acquisition (M&A) activity in Q4 2025 in the Pharma sector.
Key Highlights
- The global pharma sector in Q4 2025 saw a surge in deal value, with $80.2 billion worth of deals, representing an increase of 59.3% compared to Q3 2025. However, deal volume, declined by 12% to 103 M&A deals in Q4 2025. Oncology emerged as the leading therapeutic area recording 46 deals.
Report Scope
- This report provides an overview of M&A activity globally in Q4 2025 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q4 2025 in the Pharma sector.
Reasons to Buy
- Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Pharma M&A Analysis in Q4 2025
2.1 Pharma M&A Insights: Deal spotlight
3 Global M&A Trends in Pharma
4 Global Quarterly M&A Trends in Pharma
5 Ownership Type: Private Vs Public (Volume)
6 Ownership Type: Private Vs Public (Value)
7 Global M&A in Pharma by Deal Size Analysis
8 Top M&A Deals in Pharma Q4 2025
9 Regional M&A Comparison in Pharma - Q4 2025
10 Global Cross Border M&A Trends in Pharma
11 Inbound and Outbound M&A Deals in Pharma - Q4 2025
12 Regional M&A Trends in Pharma by Value and Volume
13 M&A Analysis in Pharma by Top 10 Countries
14 M&A Analysis in Pharma by Top 10 Therapy Areas
15 Further Information
15.1 Methodology
16 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novartis
- Avidity Biosciences
- Merck
- Cidara Therapeutics
- Novo Nordisk
- Akero Therapeutics
- BioMarin Pharmaceutical
- Amicus Therapeutics
- Johnson & Johnson
- Halda Therapeutics
- Alkermes
- Avadel Pharmaceuticals
- Sanofi
- Dynavax Technologies
- Ipsen
- ImCheck Therapeutics
- Bristol-Myers Squibb
- Orbital Therapeutics
- Swedish Orphan Biovitrum
- Arthrosi Therapeutics
- Abbott Laboratories
